John is a non-executive Director in several European biotech companies, including AgomAb, Synklino, Synact, Storm and Neophore. Prior, he was the CEO of F-star in Cambridge, UK (2012-2018), where he built a successful biotech company that initiated two clinical trials in oncology and generated more than €200M in non-dilutive revenue. From 2010 to 2012, he
Board of Directors
Mike is a founding partner of Redmile Group, LLC. Prior to Redmile, Mike was a Vice President and research analyst at Steeple Capital (September 2005 through March 2007), where he covered the biotechnology, biopharmaceuticals, research tools and diagnostics industries. Prior to Steeple, he was the medical devices analyst at Welch Capital Partners and an associate
Ohad is a Partner at Pontifax, where he is focused on scouting and project evaluation. He also serves on the board of several of Pontifax’s portfolio companies including AgomAb, Precirix, Step Pharma, Pi Therapeutics and Kamari Pharma. Ohad obtained his MSc in Biology from Tel-Aviv University.
Tim is CEO and member of the Board of Directors of Agomab. Together with the team, he has raised around $100M from top US and EU investors since joining Agomab in 2019. Prior to Agomab, Tim held the position of VP Corporate Development at AM-Pharma where he and the team executed a Phase IIb trial